Join the Oncology Voice Network. Join for Free
Be Brave-A Networking Tale that Led to Friendship
authentic networking LinkedIn connections overcoming networking fear building genuine connections networking communication skills altruism in networking networking courage

Be Brave-A Networking Tale that Led to Friendship


Share This Article


Summary

In this episode, Josh Yoder and Kirsten Borbe to share their amazing story of how a networking message on LinkedIn led to a friendship. The discussion begins with insights into Josh and Kirsten's backgrounds and networking perspectives. They emphasize the importance of authentic networking and overcoming fear, sharing strategies for building genuine connections and evolving professional relationships into friendships. Key communication skills such as brevity and authenticity are highlighted, alongside the role of altruism in networking. The conversation addresses the fear of risk and concludes with thoughts on networking courage and bravery. Closing remarks offer appreciation for the insights shared.

Key Points

  • Networking should be approached with authenticity and a genuine interest in others, rather than self-promotion.
  • Building meaningful connections often involves taking risks and embracing opportunities, even if it means stepping out of your comfort zone.
  • The real value in networking comes from helping others without expecting anything in return, which often leads to more fulfilling and long-lasting relationships.

Click for Source
authentic networking, LinkedIn connections, overcoming networking fear, building genuine connections, networking communication skills, altruism in networking, networking courage

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Value assessment of oncology drugs using a weighted criterion-based approach
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Article
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
OVN Avatar Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

Article
Outcome measures for oncology alternative payment models: practical considerations and recommendations
OVN Avatar Jakub P. Hlávka, PhD, Pei-Jung Lin, PhD, Peter J. Neumann, ScD

Outcome measures for oncology alternative payment models: practical considerations and recommendations

Article
Value assessment frameworks in oncology: championing concordance through shared standards
OVN Avatar M. Bertagnolli and J. Tabernero

Value assessment frameworks in oncology: championing concordance through shared standards

Article
Leveraging existing data to contextualize phase II clinical trial findings in oncology
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes

Leveraging existing data to contextualize phase II clinical trial findings in oncology

Explore OVN